Access Pharmaceuticals, Inc. (ACCP) Engages Edelman PR
Access Pharmaceuticals, Inc. recently hired public relations firm Edelman to increase public awareness of the company's new oral mucositis treatment MuGard. Oral mucositis, a disease that targets membranes of the mouth and gastrointestinal tract, is potentially debilitating. Houston, Texas-based Access Pharmaceuticals is a biopharmaceutical company that focuses on developing and marketing a series of proprietary products for the care of cancer patients. The company's product line includes MuGard, ProLindac (for treating ovarian cancer) and Thirabine (a new nucleoside). Access also produces the CobaCyte and CobOral drug delivery systems. Edelman is a PR firm with offices in 53 cities and 3,700…